Scarica l'app Stockscreener
5.12
7.91%
-0.44
Dopo l'orario di chiusura:
5.10
-0.02
-0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Rocket Pharmaceuticals Inc Borsa (RCKT) Ultime notizie
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Thrivent Financial for Lutherans Sells 21,731 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - MSN
Where are the Opportunities in (RCKT) - news.stocktradersdaily.com
Teacher Retirement System of Texas Raises Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year LowHere's Why - MarketBeat
Swiss National Bank Has $1.93 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
Cantor Fitzgerald maintains Overweight on Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Has $8.25 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Cantor Fitzgerald maintains Overweight on Rocket Pharmaceuticals stock - Investing.com India
(RCKT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
PNC Financial Services Group Inc. Increases Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Bank of New York Mellon Corp Buys 9,949 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Fanconi Anemia Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
What technical indicators reveal about RCKT stock - US Post News
Steward Partners Investment Advisory LLC Has $84,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Arizona State Retirement System - Defense World
BMO Capital Markets Begins Coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
(RCKT) Investment Analysis and Advice - news.stocktradersdaily.com
BMO Capital Initiates Coverage on Rocket Pharmaceuticals With Outperform Rating, $50 Price Target - Marketscreener.com
BMO Capital Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Outperform Recommendation - Nasdaq
Rocket Pharmaceuticals: A Buy Rating for Its Pioneering Gene Therapy Approach and Promising Pipeline - TipRanks
BMO Capital sets $50 target for Rocket Pharmaceuticals stock - Investing.com India
BMO Capital sets $50 target for Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Private Advisor Group LLC Acquires Shares of 13,199 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by New York State Common Retirement Fund - Defense World
Rhumbline Advisers Has $1.25 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Research Analysts Set Expectations for RCKT FY2025 Earnings - Defense World
Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Insider Monkey
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Handelsbanken Fonder AB Has $290,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $15.00 by Analysts at The Goldman Sachs Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $52.00 at Scotiabank - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $36.00 at Canaccord Genuity Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low on Analyst Downgrade - Defense World
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s Stock Adds 0.53%, Making It A Good Investment - Stocks Register
Scotiabank raises Rocket Pharmaceuticals target to $52 - Investing.com
What is William Blair’s Estimate for RCKT Q1 Earnings? - Defense World
What is Leerink Partnrs’ Estimate for RCKT Q2 Earnings? - Defense World
Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $54.00 - Defense World
Needham & Company LLC Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $42.00 - Defense World
Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs - MSN
When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit? - Yahoo Finance Australia
Decoding Rocket Pharmaceuticals Inc (RCKT): A Strategic SWOT Ins - GuruFocus
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus - MSN
Rocket Pharmaceuticals Advances Gene Therapy Pipeline - TipRanks
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month LowHere's What Happened - MarketBeat
Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target - TipRanks
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):